ANAnuprita R. Nair

Anuprita R. Nair

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anuprita R. Nair has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Strategies to establish a biologically defined Parkinson’s disease cohort prior to the onset of clinically significant motor symptoms

    by Ethan G. Brown, Helena Blumenau, David-Erick Lafontant, Anuprita R. Nair, Noah Johnson, Roy N. Alcalay, Lana M. Chahine, Christopher S. Coffey, Roseanne D. Dobkin, Tatiana Foroud, et al.

    Identifying individuals at risk for neurodegeneration is a priority for clinical trials. Parkinson’s Precision Medicine Initiative (PPMI) deploys strategies to enroll individuals before typical clinical Parkinson’s disease symptoms: recruiting polysomnogram-confirmed REM sleep behavior disorder (RBD) and central identification of hyposmia via smell testing. Groups were divided into RBD with and without hyposmia (RBD+Hyposmia, RBD-Hyposmia) and hyposmia with and without self-reported dream enactment behavior (Hyposmia+DEB, Hyposmia-DEB). Participants underwent clinical and biomarker testing including CSF alpha-synuclein seed amplification assay (CSFaSynSAA) and dopamine transporter imaging. While all enrollment strategies showed robust enrichment for CSFaSynSAA positivity, RBD+Hyposmia and Hyposmia+DEB were more likely CSFaSynSAA+ (94% and 85%) vs RBD-Hyposmia (40%) and Hyposmia-DEB (55%). Among CSFaSynSAA+, RBD+Hyposmia and Hyposmia+DEB had more mood, autonomic, and cognitive symptoms than Hyposmia-DEB. PPMI identified a large biologically-defined early neuronal synucleinopathy cohort and demonstrated biomarker and multi-domain clinical heterogeneity within CSFaSynSAA+ individuals prior to symptom onset.

  • Open Access

    SAA positivity rate amongst dual LRRK2-GBA1, GBA1 and LRRK2 carriers with Parkinson’s disease

    by Penina Ponger, Anuprita R Nair, Noah S Johnson, Chelsea Caspell-Garcia, David-Erick Lafontant, Roy N Alcalay, The Parkinson’S Progression Markers Initiative, Noah Noah

    We investigated whether people with Parkinson’s disease who are dual GBA1+LRRK2 carriers have a milder, LRRK2-like phenotype as previously reported. This was accomplished by comparing clinical features and alpha-synuclein seed amplification assay (SAA) positivity rates between dual GBA1+LRRK2-PD(n=13), GBA1-PD(n=169) and LRRK2-PD(n=175) carriers in a cross-sectional retrospective study of Parkinson’s Progression Markers Initiative (PPMI) data. Our results show that GBA1+LRRK2-PD SAA positivity rate(83%) is closer to GBA1-PD rate(87%) rather than LRRK2-PD rate(62%,p-value>0.05). GBA1+LRRK2-PD have both non-motor and motor phenotypic similarity to GBA1-PD,(p-value>0.05). This small PPMI cohort indicates that dual GBA1+LRRK2-PD carriers’ SAA positivity and phenotype are aligned with GBA1-PD.